Lilly expands infectious-disease portfolio with three-broker vaccine acquisitions
TL;DR
Eli Lilly is buying Curevo, LimmaTech Biologics, and Vaccine Company for up to $3.8 billion in upfront and milestone payments to broaden its infectious-disease pipeline. Curevo brings a shingles vaccine candidate, LimmaTech adds a Staphylococcus aureus vaccine program, and Vaccine Company offers vaccines targeting flaviviruses and an EBV-focused program, signaling Lilly’s shift toward preventative vaccines and a strategy to build a diversified vaccine portfolio alongside its strong oncology and metabolic franchises.
- Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues Fierce Biotech
- Lilly Goes on $20 Billion Buying Spree as It Seeks Next Act Yahoo Finance
- Eli Lilly to acquire Seattle-area vaccine maker for $1.5 billion The Seattle Times
- Lilly announces three acquisitions to build infectious disease portfolio | Eli Lilly and Company investor.lilly.com
- Three vaccine biotechs to be bought by Lilly for up to $3.8B Endpoints News
Want the full story? Read the original reporting
Read on Fierce Biotech